Achour and co-workers have previously demonstrated that vaccinationwith H-2Db-restricted APLs, in which peptide position 3was modified to a proline (p3P), increased significantly immune responsestoward targets presenting tumor-associated epitopes.23,25,26,29−31 Indeed, the p3P modification in the H-2Db-restricted melanoma-associated TAA gp10025-33 andthe TEIPP-neoantigen Trh4 increased binding affinity to their cognateTCRs pMel and LnB5, respectively, resulting in significantly strongerin vivo and in vitro immune responses by endogenous CD8+ T cell populations toward cancer targets. This evidence concerns the gene CD8A and cancer.